MSK Research Highlights, October 13, 2022
New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute suggests a therapeutic strategy to overcome resistance to PRMT5 inhibition in lymphoma; finds safety and clinical benefit using an engineered adenovirus in combination with immunotherapy against PD-1-resistant melanoma; and uncovers a new type of immune cell that plays a key role in establishing a healthy gut microbiome.
Memorial Sloan Kettering Establishes Tow Center for Developmental Oncology to Better Understand and Treat Cancers that Affect Children and Young Adults
MSK announces the establishment of The Tow Center for Developmental Oncology (TCDO).
In the Lab
Newly Discovered Immune Cell Subtypes Could Shake Up Immunotherapy
Dendritic cells, the guards of the immune system, have a previously unrecognized division of labor.
